Collegium Pharmaceutical Inc buy tamam
Start price
21.06.18
/
50%
€24.70
Target price
03.06.19
€36.08
Performance (%)
-57.85%
End price
03.06.19
€10.41
Summary
This prediction ended on 03.06.19 with a price of €10.41. Massive losses of -57.85% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Collegium Pharmaceutical Inc | -1.274% | -1.274% | 15.672% | 58.163% |
| iShares Core DAX® | 0.855% | 1.375% | 2.609% | 52.294% |
| iShares Nasdaq 100 | -0.989% | -3.844% | 25.552% | 78.877% |
| iShares Nikkei 225® | -1.781% | -8.530% | 42.813% | 65.506% |
| iShares S&P 500 | 0.057% | 0.610% | 21.574% | 63.546% |
Comments by tamam for this prediction
In the thread Collegium Pharmaceutical Inc diskutieren
Collegium in a huge potential market and solid operational momentum
Collegium continues to see a nice ramp-up in sales of Xtampza.
First-quarter revenues should be very strong as well, as regulatory action following the opioid crisis could make Xtampza a big winner.
(Vom Mitglied beendet)